Liver Cancer News

Blue Faery: The Adrienne Wilson Liver Cancer Association

AA

A A

Liver Cancer News

Print Friendly, PDF & Email

Click on the title to read the rest of the Liver Cancer News story.

Japan’s Eisai Sets Price Tag Of About US $17,000 On Liver Cancer
17 August 2018
The Japanese pharmaceutical company Eisai has set the price of US $16,970 for a 30-day supply of Lenvima for wholesalers. Lenvima is a medication for “previously untreated patients with an advanced or intermediate stage of unresectable hepatocellular carcinoma.” According to Thomson Reuters data, Lenvima is predicted to bring in US $3.46 billion by 2022.

Liver Cancer Screening Did Not Reduce Mortality In Cirrhosis Cases
16 August 2018
The type of screenings used for Hepatocellular Carcinoma do not change the prognosis of individual patients. There are multiple types of screening processes for HCC, and Dr. Andrew M. Moon of the University of North Carolina found no correlation between the type of screening that a patient receives and HCC-related mortality.

FDA Oks First-Line Tx For Unresectable Liver Cancer
16 August 2018
The FDA approved a new medication called Lenvima, a kinase inhibitor lenvatinib, as a first-line treatment for hepatocellular carcinoma (HCC) with unresectable disease. REFLECT is the phase three clinical trial that showed such positive results in regards to progression-free survival, that Lenvima was the first “first-line” systemic therapy option in the past ten years.

Hep C ‘Cure’ Doesn’t Eliminate Liver Cancer Recurrence
14 August 2018
For Hepatitis C patients who have responded well to direct-acting antivirals (DAA), there is still a need to follow-up with doctors. This is because there is not enough long-term information on how curing Hepatitis C patients may affect other clinical outcomes like the potential for Hepatocellular Carcinoma. The need to monitor patients came from Dr. Sonal Singh from The University of Massachusetts School of Medicine in Worcester.

Preoperative Antivirals Lower Recurrence Risk In HBV-Related Liver Cancer
14 August 2018
For patients with Hepatocellular Carcinoma that is Hepatitis-B related, there is good news. In a study done in Shanghai, patients who were treated with antiviral therapy (AVT) before surgery had a reduced risk of tumor recurrence. The AVT was given for more than 90 days prior to surgery, which made the significant difference. Patients who were given a shorter-term treatment of AVT did not find the same results. Feng Shen conducted the study at the Second Military Medical University.

Scientists Develop Novel Drug That Could Potentially Treat Liver Cancer More Effectively
3 August 2018
A novel peptide drug called FFW is a small chain of amino acids that would act as a cancer-cell-specific target and this may develop into a clinical grade drug used for patients with Hepatocellular Carcinoma (HCC). The researchers Daniel Tenen and Dr. Liu Bee Hui are working at the Cancer Science Institute of Singapore and are part of the team working to bring FFW to patients in hopes of stopping the development of HCC.

Direct Antiviral Therapy Of Hepatitis C
2 August 2018
The risk of developing hepatocellular carcinoma (HCC) did not increase after patients took direct antiviral therapy (DAA). The cirrhotic patients who achieved sustained viral response (SVR) through DAA were not more likely to develop HCC after DAA treatment.

Clinical Significance Of The Isolated Anti-Hbc Serologic Pattern
2 August 2018
“The clinical significance of isolated anti-HBc (IAHBc) includes Hepatitis B virus (HBV) transmission and HBV reactivation in the context of immunosuppressant therapy. The development of liver fibrosis and hepatocellular carcinoma [additional concerns].”

Okyeama Kwame Offers Hepatitis B Free Screening
1 August 2018
Free Hepatitis B screenings and vaccinations were performed for thousands of Ghanaians to honor this year’s World Hepatitis B Day. The Okyeama Kwame Foundation (OKF) worked with the MDS Lancet Laboratory and the Ghana Health Service (GHS) to put on the event and raise awareness in hopes of preventing chronic infections.

AMC Treats Egyptian Surgeon With Multiple Hepatocellular Carcinomas
31 July 2018
Shananm Mohamed is an Egyptian surgeon who underwent laparoscopic surgery for a six-centimeter tumor caused by HCC. He traveled to Seoul, South Korea to get the surgery because there was no laparoscopic equipment or surgeons in Egypt. Professor Kim-Ki-Hun performed the surgery successfully at Asan Medical Center (AMC).

Wuxi STA And Antengene To Collaborate On Cancer Drug Development
27 July 2018
The collaboration between companies WuXi STA and Antengene is starting with hepatitis B virus- positive advanced Hepatocellular Carcinoma patients. The biopharmaceutical companies are working on a molecule called ATG-008 in this clinical trial.

Tackling Liver Cancer Using CRISPR To Develop A New Animal Model
17 July 2018
The Southwest National Primate Research Center at Texas Biomed is using Old World Monkeys as a new animal model, as the mouse models were failing when adapted to human trials. There is more hope with a larger animal, and Dr. Christopher Chen says that CRISPR is “really making a huge impact in labs around the country.”

Liver Cancer Death Rate In US Surged 43% In 16 Years
17 July 2018
In American adults, the death rates for liver cancer increased an incredible 43% from 2000 to 2016. Both men and women over age 25 and older saw this increase, while only Asians and Pacific Islanders saw a decrease in the mortality caused by liver cancer. This increase is shocking, as overall mortality for all cancers has declined.

Liver Cancer Risks, Detection: 8 Recent Reports
16 July 2018
‘Healio presents the following recent reports that include studies on ethnic differences in liver cancer detection, improved diagnosis and bi-annual screening, and innovative noninvasive testing solutions’. This new data is beneficial for patients who are looking for more information about HCC.

Tenofovir For Chronic HBV Reduces Risk For Hepatocellular Carcinoma
16 July 2018
Tenofovir Disoproxil (TDF) is a treatment that may significantly reduce the risk of HCC for patients who have chronic hepatitis B infection. TDF was ‘significantly associated with an 8-year Hepatocellular Carcinoma cumulative (HCC) incidence rate reduction among cirrhotic and non-cirrhotic patients”.

Life-Saving Liver Cancer Screening For Hepatitis C Patients
12 July 2018
‘Doctors say lives can be saved if people with Hepatitis C are identified and encouraged to be screened for liver cancer. It requires a blood test and an abdominal ultrasound.” A patient named Neil Strassman contracted Hepatitis C and had no symptoms, so he was unaware until getting a diagnosis in 2006. He developed liver cancer, but after a successful liver transplant in 2012, he is now cancer-free.

Keytruda sBLA Granted Priority Review For Advanced Hepatocellular Carcinoma
11 July 2018
The promising results from the Phase 2 KEYNOTE- 224 Trial have led to a new supplemental Biologics License Application (sBLA) for Pembrolizumab. The medication has been granted priority review by the Food and Drug Administration (FDA).

OBI Pharma Granted FDA Orphan Drug Designation For OBI-3424 For The Treatment Of Hepatocellular Carcinoma (HCC)
9 July 2018
OBI-3424 is the first medication in its class that is being used to target solid tumors in patients with Hepatocellular Carcinoma (HCC) and castrate-resistant prostate cancer (CRPC). The Phase ½ study has begun enrollment at the University of Texas M.D. Anderson Cancer Center.

DAA HCV Therapy Possible In Successfully Treated Hepatocellular Carcinoma
6 July 2018
Using direct-acting antivirals (DAAs) and ribavirin (RBV) in the treatment of hepatitis C virus (HCV) has promising results. For patients who found radiologic response from HCC, this treatment method for HCV is being done in current studies.

Cabozantinib Improves Survival In Advanced Hepatocellular Cancer
6 July 2018
Cabozantinib is shown to be effective in progression-free survival in HCC patients in a study done by Dr. Ghassan K. Abou-Alfa at Memorial Sloan Kettering Cancer Center. The 707 patients were given either a placebo or Cabozantinib and the medication was proven more successful than placebo.

FDA Expedites Tecentriq-Avastin Combo For Most Common Liver Cancer
5 July 2018
Genentech launched the IMbrave150 Phase 3 clinical trial for the combination of Tecentriq and Avastin for the treatment of unresectable or metastatic Hepatocellular Carcinoma. In a press conference, Dr. Sandra Horning said, “Preliminary data from the combination of Tecentriq and Avastin in this disease are promising and we look forward to working with health authorities to make this potential treatment regimen available to people with Hepatocellular Carcinoma as soon as possible.”

Experts Anticipate A Growing Menu Of Frontline Options In Liver Cancer
4 July 2018
According to Dr. Aiwu Ruth He: ‘The landscape for Hepatocellular Carcinoma is shifting. I suspect we will have more frontline therapy options to choose from.’ This promising statement was issued during the Peer Exchange panel discussion, where new therapies like regorafenib (Stivarga) and nivolumab (Opdivo) were discussed.

Medical Minute: Engineering T-Cells To Target Liver Cancer
2 July 2018
Dr. Joseph Hobbs of the Medical College of Georgia at Augusta University speaks about the progress that is being made for liver cancer in engineering human T-cells. “The Medical Minute is written and produced by The Medical College of Georgia at Augusta University.”

20,000 Vietnamese Die Of Liver Cancer Each Year
27 June 2018
Vietnam has a population of 95 million people. The cited reasons for the liver cancer death rate is due to “late diagnosis and treatment.”

Better Buy: Exelixis, Inc. Vs Immunogen, Inc.
26 June 2018
The cancer drug Cabozantinib, created by Exelixis, Inc. is going under an FDA review in the hopes of getting the drug extended to treat liver cancer. Cabozantinib is a pill that was originally created for treatment of kidney cancer.

Son Of Cream Legend Jack Bruce Hails His Dad’s Genius And Reveals Special Plans To Celebrate Band’s Legacy
25 June 2018
Jack Bruce was diagnosed with liver cancer in 2003 and was not expected to survive long-term. He reunited with two members of his band Cream in Albert Hall in 1968 and had a 50th Anniversary World Tour. Jack’s son is now celebrating his father’s legacy.

Allan Ralph Cooper Dies
25 June 2018
Allan Cooper passed away from his battle with liver cancer on June 17th, 2018 in Truckee, CA. He was a member of the US Army for 3 years and worked for the Continental Federal Credit Union for 33 years. He has surgery to remove a portion of his liver but was unable to pull through with the remaining portion of his liver.

Perioperative Antivirals Reduce HBV Reactivation After Transarterial Chemoembolization
25 June 2018
For HCC patients, taking antiviral therapy before getting transarterial chemoembolization (TACE) may improve liver function. This new research is an exciting step forward in the treatment of Hepatocellular Carcinoma.

These Symptoms, Pointing to Liver Cancer The Chronicle of World Events
25 June 2018
According to the British organization Cancer Research UK, potential signs of liver cancer are: a loss of appetite and weight that can’t be identified, swelling of belly, and nausea.

Benefits Of Coffee
23 June 2018
The antioxidants in coffee have been linked to a lowered risk of liver cancer. Specifically, caffeinated coffee has a benefit in reducing cancer risk.

Global Hepatocellular Carcinoma (HCC) Epidemiology Forecast To 2027, With Coverage Of 8 Major Markets Including United States, EU5 Countries, China & Japan 
22 June 2018
The research in this report shows that the total number of incident cases for HCC in G8 countries in 2016 was 458,170.

Levantinib-Pembrolizumab Shows Promise In Several Cancer Types
22 June 2018
There is current research in the use of Levantinib (Lenvima, Eisai) and Pembrolizumab (Keytruda, Merck) for patients with Hepatocellular Carcinoma, renal cell carcinoma, endometrial cancer, and head and neck cancers. The advance of these research trials is bringing hope to patients.

Dr. Finn Recaps Second-Line Advancements In HCC
22 June 2018
In the last year and a half, ‘there have been many advancements in the management of patients with advanced HCC’. The two medications that have shown positive results are Stivarga and Lenvima.

Resveratrol And Cancer
22 June 2018
It is difficult for humans to absorb but Resveratrol is a polyphenol (antioxidant) that has been shown to have anti-cancer effects. The compound can be found in grapes, red wine, berries and peanuts.

NCCN Offers New Resource For Patients With Hepatobiliary Cancers
21 June 2018
The National Comprehensive Cancer Network (NCCN) is releasing a new edition of their guidelines for patients with liver, gallbladder, and bile duct cancers. This is to assist patients with more information to understand their treatment decisions.

B.C. Transplant May Accept Hepatitis C Positive Donors Now That There’s A Curative Drug Treatment For Recipients Who Contract It
21 June 2018
Because of the drugs that are able to cure hepatitis C, doctors such as Dr. David Landsberg are beginning trials that transplant organs from Hep C patients to patients who are in need of a transplant to survive.

Adding SIRT Does Not Provide Survival Benefit In Advanced HCC, Except In Select Patients
20 June 2018
In patients with advanced Hepatocellular Carcinoma, Selective internal radiation therapy (SIRT) in combination with Nexavar does not significantly improve survival in comparison to solely taking Nexavar. But there is a subgroup of patients who may find a benefit in this combination therapy.

Hardiwar-Based Scientist Claimed Herbal Breakthrough for Hepatocellular Carcinoma
13 June 2018
Dr. Hemanth is studying a new pathway to treat Hepatocellular Carcinoma and is planning to patent the pathway and natural drugs that lower AFP (alpha-fetoprotein). Because Hepatocellular Carcinoma is considered ‘highly chemo-resistant’, finding this new pathway may be a beneficial new approach to treating the cancer.

Merck KGaA Give A Good Hint Of Efficacy In A Special Form Of Liver Cancer
13 June 2018
For patients with advanced Hepatocellular Carcinoma, there are positive results from two phase-2 clinical trials done by Merck. The drug Tepotnib, is being used as first-line and second-line treatment for tumors that have the gene MET mutation.

Celsion Corporation: A Summer Of Catalysts
12 June 2018
The Optima Trial is a phase 3 trial for lung cancer patients. The company Celsion expects to have complete enrollment of 550 patients by the end of the summer. This is good news for the Celsion, as their previous study ThermoDox did not have success as standardized heat treatment for patients.

Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel To Accurately Diagnose Hepatocellular Carcinoma
8 June 2018
Researchers at Exact Sciences Corp. and Mayo Clinic announced significant progress toward developing a panel of novel, blood-based, DNA biomarkers that could accurately detect Hepatocellular Carcinoma (HCC), the most common cancer that originates in the liver. The researchers detailed their findings during a presentation today at Digestive Disease Week, the world’s largest gathering of gastroenterologists and scientists in the field.

Using Cell-Free DNA As A Marker For Liver Cancer Diagnosis
1 June 2018
Dr. Kang Zhang is interviewed about his diagnostic work at the Laboratory for Advanced Medicine (LAM). He is a geneticist and a physician who is looking at a very specific area of DNA to identify liver cancer.

For past liver cancer news, please visit our Liver Cancer News Archives.

Scroll Up